DeepIntent vs IQVIA vs PulsePoint for Pharma

One of the most common questions I field from brand teams, especially those moving budget into programmatic for the first time, is whether they should use DeepIntent, IQVIA’s programmatic offering, or PulsePoint. My short answer is always the same: it depends on whose data stack you are already inside, where your compliance posture sits, and whether your primary audience is prescribers or patients. The longer answer is what follows.

Everything here reflects my own working experience across healthcare DSPs including DeepIntent, The Trade Desk, DV360, and PulsePoint, combined with hands-on measurement work through Veeva Crossix and IQVIA. This is informed practitioner opinion, not vendor benchmarking or official comparative research. Platform capabilities evolve, and your mileage will vary by therapy area, brand size, and team configuration.

Why DSP choice in pharma is really a data and compliance decision

In consumer programmatic, DSPs compete primarily on reach, algorithm quality, and integrations with brand-safe inventory. The underlying data is commodity: age, gender, behavioral interest, purchase intent. Most DSPs can access the same pools.

In pharma, that commodity logic breaks down fast. The audiences that matter, physicians segmented by specialty and NPI, patients modeled off condition-adjacent signals, prescribers stratified by decile, exist inside proprietary data assets built by a small number of healthcare data companies. Those assets are not open-exchange interchangeable. A DSP that natively integrates a claims-informed HCP data spine gives you fundamentally different targeting fidelity than one where the healthcare audience is a bolt-on third-party segment.

Compliance adds a second layer. Targeting rules around health-condition inference, device-level ID handling under HIPAA’s shadow, and the downstream question of how measurement is conducted, all of these shape which platforms a legal and regulatory team will actually sign off on. Picking a DSP that your MLR team cannot clear is not a media decision; it is a months-long delay. For a deeper grounding in the data layer, see The Ultimate Guide to Pharma Programmatic Advertising.

The evaluation criteria that actually matter

When I assess a healthcare DSP for a new brand or campaign, I work through six dimensions in roughly this order:

• HCP and NPI data depth: Does the platform have a native, continuously refreshed NPI-linked audience, or does it rely on third-party segments layered on top of a general-purpose DSP? The former gives you deterministic HCP reach; the latter introduces matching latency and ID coverage gaps.
• Claims and Rx data integration: Can the platform onboard de-identified prescribing data to refine targeting, suppressing current writers, prioritizing high-decile targets, or finding lookalikes off a brand’s own patient seed? This is the difference between specialty targeting and brand-relevant specialty targeting.
• Compliance and HIPAA posture: Has the platform published a formal HIPAA-compliant infrastructure position? Does it operate a Business Associate Agreement (BAA) framework? How does it handle sensitive-health-condition exclusions and audience suppression?
• Measurement partners: Which outcomes measurement integrations are native versus custom? Crossix, IQVIA Rx, and Symphony Health are the primary scripts-linkage layers. The tighter the native integration, the faster you get closed-loop reporting without a manual data-sharing agreement on every campaign.
• Inventory quality and CTV: Where does the platform source its supply, and how robust is its connected TV footprint? CTV is now a primary channel on most pharma plans, and endemic-plus-extension supply models differ materially across platforms.
• Service model and managed support: Pharma campaigns move through MLR review, have compressed launch windows, and carry fair-balance requirements that affect creative trafficking. White-glove managed service versus self-serve matters here in ways it does not in most verticals.

DeepIntent: built from the ground up for HCP

DeepIntent is the platform I have seen perform most consistently for HCP-first campaigns, and the reason is structural rather than cosmetic. The company was founded specifically for healthcare advertising, which means its data infrastructure, NPI-linked audience graphs, endemic publisher relationships, and outcomes measurement hooks, were designed together rather than assembled through acquisition.

Its core targeting mechanism runs on a proprietary healthcare identity graph that links NPI records to digital identifiers across devices, refreshed on a cadence designed to account for physician mobility and practice changes. For a brand trying to reach cardiologists across a specific prescribing decile, that deterministic foundation matters. You are not hoping a third-party healthcare segment covers your audience; you are targeting from the NPI list down.

On the measurement side, DeepIntent has built direct integrations with Crossix and other outcomes partners, which reduces the manual effort required to connect campaign exposure to script lift. The platform’s outcomes-based optimization, using Crossix signals to bid toward audiences with higher conversion propensity, is a genuine differentiator when the campaign objective is NRx growth rather than awareness.

The tradeoffs are real. DeepIntent is a purpose-built healthcare platform, which means it does not carry the breadth of open-web or general-audience inventory that a horizontal DSP does. For campaigns with a meaningful DTC component, you will likely need a companion platform or supplementary buying layer. The self-serve tooling, while improving, is still weighted toward managed service for complex HCP campaigns, which requires factoring in lead time and support dependency. Budget minimums also skew higher than a general-purpose DSP.

IQVIA: the data-heritage advantage

IQVIA’s programmatic offering, operating under its Orchestrated Customer Engagement (OCE) and programmatic media suite, carries a different kind of weight. IQVIA is, at its core, a healthcare data and analytics company. It owns one of the largest de-identified longitudinal patient and prescriber data assets in the industry. When IQVIA activates a programmatic campaign, the audience is being drawn from the same data spine that biopharma companies use for sales force deployment, market research, and brand tracking.

That heritage translates into genuine depth on claims-level targeting and outcomes measurement. If your brand is already using IQVIA data for sales analytics, the connective tissue between media targeting and measurement is considerably shorter than it would be with a platform that has to license the same data externally. The closed-loop, from audience creation through exposure to Rx outcome, can operate within a single data environment, which reduces reconciliation friction and tightens the feedback loop for optimization.

The tradeoffs center on the programmatic platform experience itself. IQVIA’s media activation capability has grown meaningfully, but it remains most powerful when the full analytics and data ecosystem is engaged. Teams running a pure media buy without the broader IQVIA data relationship may find the platform’s differentiation less pronounced. The interface and campaign-management experience is more analytics-oriented than media-practitioner-oriented, which creates a learning curve. And like DeepIntent, the platform’s strongest footing is HCP; DTC campaigns benefit less directly from the Rx-heritage data layer.

PulsePoint: contextual depth and condition audiences

PulsePoint, acquired by Internet Brands and closely integrated with WebMD Health, occupies a distinct position in the healthcare DSP landscape. Its core differentiation is contextual, native access to condition-level content environments across the WebMD, Medscape, and related publisher network, combined with HCP audience data built from that endemic supply.

For DTC campaigns, that contextual foundation is a meaningful edge. A patient researching a specific condition on a WebMD property is a high-intent signal that a de-identified model off third-party data cannot replicate. PulsePoint can activate against those contextual moments programmatically, at scale, with a compliance posture appropriate for condition-adjacent (rather than condition-specific) targeting. This makes it a natural fit for unbranded disease-awareness campaigns, OTC adjacency, and patient-journey moments where contextual relevance is more defensible than behavioral inference.

On the HCP side, PulsePoint carries Medscape and physician-facing inventory natively, giving it genuine endemic reach into the clinical decision-making environment. That said, its NPI-deterministic targeting depth has historically been less its primary identity than it is for DeepIntent. The platform tends to shine when the strategy leans on contextual placement and condition-aligned audiences rather than prescriber-list granularity.

Tradeoffs include a CTV footprint that is still building relative to the other two, and a measurement integration story that benefits most from brands already invested in the Internet Brands / WebMD data ecosystem. For pure HCP-deterministic campaigns built around script-lift optimization, the platform requires more supplementation. For more on HCP targeting considerations that cut across platforms, see Mastering HCP Targeting Best Practices.

Side-by-side comparison

How to actually decide

The honest answer is that most sophisticated pharma programs do not pick one platform and stop there. They assign lead DSPs by audience type and supplement based on measurement or inventory needs. Here is the decision logic I use with brand teams:

If HCP targeting is the primary objective, especially specialty targeting where NPI determinism matters and the outcome is NRx lift, DeepIntent is typically the default consideration. The platform was built for this job, and the Crossix measurement integration makes script-lift reporting operationally straightforward. IQVIA is the strongest alternative or complement when the brand already operates in the IQVIA data ecosystem and wants the analytics and media to share a data language.

If DTC or unbranded disease awareness is the lead use case, particularly condition-contextual or patient-journey moments, PulsePoint’s endemic inventory and contextual model are worth leading with. The compliance story is cleaner because you are targeting context rather than inferring health status, and the WebMD audience signal is genuinely high-intent.

If measurement architecture is the deciding factor, if your brand’s commercial analytics are already running on IQVIA data and the team needs a single consistent data spine from targeting through outcomes reporting, IQVIA’s programmatic offering reduces integration overhead meaningfully. That reduction compounds over a multi-quarter campaign cycle.

Therapy area matters too. Rare disease and specialty brands with tight, named prescriber lists almost always benefit from DeepIntent’s NPI-deterministic model. Primary-care and mass-market DTC brands may find PulsePoint’s contextual scale more efficient. Brands straddling both audiences, which is most branded Rx launches, often run DeepIntent for HCP alongside PulsePoint or a horizontal platform for DTC, unified by a consistent measurement partner. I walk through how measurement ties these executions together in How Programmatic Media Drives Rx Outcomes.

No single platform is the universal answer. The right starting point is clarity on your primary audience, your existing data relationships, and what your measurement team can operationally support, then let those constraints narrow the field.